Xencor to Participate in Upcoming Investor Conferences
Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the
treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced that company management will participate in
two upcoming conferences:
- Jefferies 6th Annual IO Cell Therapy Summit
Date: Friday, April 5, 2019
Location: Boston, MA
- 18th Annual Needham Healthcare Conference
Date: Tuesday, April 9, 2019
Presentation Time: 2:10 p.m. ET
Location: New York, NY
A live webcast of the Needham Healthcare Conference presentation will be available under "Events & Presentations" in the
Investors section of the Company's website located at
https://investors.xencor.com/events.cfm. A replay of the event will be posted on the Xencor website approximately one hour
after the live event and will be available for 90 days following the event.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of
cancer, autoimmune disease, asthma and allergic diseases. Currently, 12 candidates engineered
with Xencor's XmAb® technology are in clinical development internally and with
partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies
resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
Charles Liles
626-737-8118
cliles@xencor.com
Media Contact
Jason I. Spark
Canale Communications
619-849-6005
jason@canalecomm.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005858/en/